Compare ASRV & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASRV | MNOV |
|---|---|---|
| Founded | 1983 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.2M | 67.9M |
| IPO Year | 1994 | 2004 |
| Metric | ASRV | MNOV |
|---|---|---|
| Price | $4.41 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 13.5K | ★ 53.5K |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $14,634,000.00 | $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | $38.09 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $2.64 | $1.17 |
| 52 Week High | $4.49 | $1.96 |
| Indicator | ASRV | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 69.72 | 44.92 |
| Support Level | $3.62 | $1.30 |
| Resistance Level | N/A | $1.52 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 78.08 | 25.00 |
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.